Recently, Kang et al. [22] reported a randomized phase III trial comparing nivolumab (programmed cell death protein 1 (PD-1) receptor inhibitor) with a placebo in 493 Asian patients with metastatic or recurrent GC who had received at least two prior regimens. This evidence concerns the gene PDCD1 and gastric cancer.